Molecularly diagnosed glioblastoma: clinical presentation and outcomes
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-026-05752-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Harold F Hounchonou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany. hounchonou.harold@mh-hannover.de. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Background
The 2021 WHO classification permits diagnosis of glioblastoma in IDH-wildtype diffuse astrocytic tumors with TERT promoter mutation, EGFR amplification, or chromosome 7 gain/10 loss, even without necrosis or microvascular proliferation. The clinical behavior of these molecularly defined glioblastomas (molGBM) remains uncertain.
Methods
We retrospectively analyzed patients with molGBM treated at Hannover Medical School between 2017 and 2024. A contemporaneous histologically defined glioblastoma cohort (hisGBM) served as a control group in an approximately 1:3 ratio. MolGBM were stratified by histological grade and additionally compared with IDH-mutant astrocytomas of corresponding grade. Survival was assessed using Kaplan-Meier analysis, Cox regression, and propensity score matching.
Results
Thirty-four patients with molGBM and 103 with hisGBM were included. Compared with hisGBM, molGBM patients were younger ( p < 0.001), had higher Karnofsky Performance Status ( p < 0.001), and more often presented with seizures ( p = 0.006), whereas focal neurological deficits were more frequent in hisGBM. MolGBM showed less contrast enhancement ( p < 0.001) and lower Ki-67 indices ( p < 0.001). Median overall survival was longer in molGBM (539 vs. 374 days; p = 0.032), but tumor group was not independently associated with survival after adjustment for age and KPS (HR 1.21, 95% CI 0.77–1.90; p = 0.411). In the matched cohort, overall survival did not differ significantly (517 vs. 468 days; p = 0.670). MolGBM had inferior survival to grade-corresponding IDH-mutant astrocytomas ( p < 0.001).
Conclusions
MolGBM shows a distinct clinical-radiological phenotype, while its apparent survival advantage over hisGBM is influenced by baseline clinical differences. Clinical trial number Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany. hounchonou.harold@mh-hannover.de.
- Department of Neurosurgery, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany.
- Department of Neuropathology, Hannover Medical School, Carl Neuberg Straße 1, 30625, Hannover, Germany.
ORCID-Profile: Harold F Hounchonou
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Hounchonou, H. F., Polemikos, M., Pirayesh, A., Bajgora, G., Al-Afif, S., Hartmann, C., & Krauss, J. K. (2026). Molecularly diagnosed glioblastoma: clinical presentation and outcomes. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05752-8
Vancouver
Hounchonou HF, Polemikos M, Pirayesh A, Bajgora G, Al-Afif S, Hartmann C, et al. Molecularly diagnosed glioblastoma: clinical presentation and outcomes. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05752-8
BibTeX
@article{Hounchonou2026,
author = {Hounchonou, Harold F and Polemikos, Manolis and Pirayesh, Ariyan and Bajgora, Genis and Al-Afif, Shadi and Hartmann, Christian and Krauss, Joachim K},
title = {Molecularly diagnosed glioblastoma: clinical presentation and outcomes},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-026-05752-8}
}
EUVIMED